| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849) | TCR2 Therapeutics | 2022-06-21 |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion (NCT05245500) | Bristol-Myers Squibb | 2022-06-09 |
| A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (NCT05365581) | Astellas Pharma Global Development, Inc. | 2022-06-07 |
| EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients (NCT05247164) | IRCCS San Raffaele | 2022-05-17 |
| Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors (NCT05181605) | Instituto de investigación e innovación biomédica de Cádiz | 2022-04-15 |
| Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC (NCT04605913) | Mayo Clinic | 2022-04-01 |
| FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer (NCT05077800) | Colin D. Weekes, M.D., PhD | 2022-03-21 |
| Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma (NCT05228808) | Sohag University | 2022-02-01 |
| 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma (NCT05239182) | Anwaar Saeed | 2022-01-26 |
| Panc CA Risk Model & Biomarker Testing In High-Risk Cohort (NCT05287347) | Beth Israel Deaconess Medical Center | 2022-01-01 |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (NCT05000294) | University of Florida | 2021-12-07 |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (NCT05059444) | Guardant Health, Inc. | 2021-09-07 |
| ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing (NCT05380557) | Invitae Corporation | 2021-08-23 |
| mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma (NCT04986930) | Asan Medical Center | 2021-08-14 |
| Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma (NCT04983407) | Aravive, Inc. | 2021-07-28 |
| Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC) (NCT04926467) | Baylor Research Institute | 2021-07-23 |
| Activation of Biobank Registry for Bilio-pancreatic Diseases (NCT06552078) | IRCCS San Raffaele | 2021-06-09 |
| NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer (NCT04539808) | OHSU Knight Cancer Institute | 2021-05-27 |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (NCT04895709) | Bristol-Myers Squibb | 2021-05-27 |
| The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer (NCT04902352) | University Hospital Birmingham NHS Foundation Trust | 2021-04-06 |
| Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. (NCT04835064) | Fudan University | 2021-04-01 |
| An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pancreatic or Stomach Cancer Receiving Chemoradiation Therapy Before Surgery, SurgeryStrong Study (NCT05056805) | M.D. Anderson Cancer Center | 2021-03-04 |
| Portal Vein Thrombosis Associated With Unresectable Pancreatic Cancers : a Prospective Multicentric Cohort Study (NCT04814251) | Poitiers University Hospital | 2021-03-01 |
| Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery (NCT04452461) | Hamilton Health Sciences Corporation | 2021-03-01 |
| Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study (NCT04837118) | M.D. Anderson Cancer Center | 2021-02-15 |
| INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors (NCT04436679) | University Hospital, Lille | 2021-02-02 |
| Pancreatic Cancer Biomarker Study (NCT04143152) | Van Andel Research Institute | 2021-01-01 |
| Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency (NCT04098237) | Andrew Hendifar, MD | 2020-12-17 |
| Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (NCT03740256) | Baylor College of Medicine | 2020-12-14 |
| Magnetic Resonance Guided High Intensity Focused Ultrasound in Advanced Pancreatic Adenocarcinoma Treatment (NCT04298242) | Stanford University | 2020-11-22 |
| Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (NCT04002479) | Alpha Tau Medical LTD. | 2020-10-20 |
| Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors (NCT04400357) | Ruijin Hospital | 2020-09-28 |
| Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer (NCT04627246) | Centre Hospitalier Universitaire Vaudois | 2020-09-11 |
| Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico (NCT05305001) | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 2020-09-09 |
| Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer (NCT03245541) | Memorial Sloan Kettering Cancer Center | 2020-08-14 |
| Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (NCT04157127) | Diakonos Oncology Corporation | 2020-08-03 |
| Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer (NCT05400681) | Sonke Detlefsen | 2020-08-01 |
| FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX (NCT04167007) | Assistance Publique - Hôpitaux de Paris | 2020-07-20 |
| KEBI-Cyto Study - Use of the Biocartis Idylla (NCT04236102) | Royal Cornwall Hospitals Trust | 2020-07-07 |
| Assessment of What Patients and Healthcare Providers Value (NCT04483349) | M.D. Anderson Cancer Center | 2020-06-11 |
| Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors (NCT04400383) | CARsgen Therapeutics Co., Ltd. | 2020-06-04 |
| PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos) Study of Risk Factors for Exocrine Pancreatic Neoplasms. (NCT06815172) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2020-05-28 |
| Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer (NCT04257448) | GWT-TUD GmbH | 2020-05-25 |
| Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies (NCT04361708) | University of Chicago | 2020-05-08 |
| Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer (NCT04406571) | CHU de Reims | 2020-04-01 |
| Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma (NCT04270929) | Roger Williams Medical Center | 2019-12-23 |
| Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (NCT03816358) | National Cancer Institute (NCI) | 2019-12-09 |
| PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer (NCT04119362) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-10-24 |
| A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer (NCT04137536) | Memorial Sloan Kettering Cancer Center | 2019-10-17 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers (NCT04077372) | Stanford University | 2019-09-16 |
| Selective Transvenous Chemoembolization of Primary Pancreatic Tumors (NCT03865563) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-07-01 |
| Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer (NCT04130399) | Indiana University | 2019-07-01 |
| PDAC Peripheral and Portal Vein Sampling (NCT04289961) | The Christie NHS Foundation Trust | 2019-06-12 |
| Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors (NCT03851614) | University Health Network, Toronto | 2019-04-08 |
| Peptide-based Immunization for Colon- and and Pancreas-carcinoma (NCT03871790) | CENTOGENE GmbH Rostock | 2019-04-01 |
| The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma (NCT04765410) | Carol Davila University of Medicine and Pharmacy | 2019-03-21 |
| Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases (NCT03856658) | Corewell Health West | 2019-02-05 |
| RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma (NCT03745430) | Hellenic Cooperative Oncology Group | 2019-01-29 |
| A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers (NCT03840460) | Royal Marsden NHS Foundation Trust | 2019-01-10 |
| 9-ING-41 in Patients With Advanced Cancers (NCT03678883) | Actuate Therapeutics Inc. | 2019-01-04 |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma (NCT03483038) | University of Florida | 2018-12-13 |
| Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer (NCT03723915) | Northwestern University | 2018-11-14 |
| Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas (NCT04773769) | Auxilio Mutuo Cancer Center | 2018-11-07 |
| EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX (NCT03126435) | SynCore Biotechnology Co., Ltd. | 2018-10-16 |
| Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer (NCT03703063) | Benaroya Research Institute | 2018-09-17 |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (NCT03665441) | ERYtech Pharma | 2018-09-15 |
| Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer (NCT03673423) | Ospedale San Raffaele | 2018-09-05 |
| Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma (NCT03376659) | Georgetown University | 2018-08-08 |
| Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma (NCT03649035) | Istituto Clinico Humanitas | 2018-07-12 |
| A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors (NCT03592264) | OBI Pharma, Inc | 2018-07-02 |
| Study Comparing Pancreatic EUS-FNB With the 20-gauge Procore® and the 22-gauge Acquire® Needles (NCT03567863) | Société Française d'Endoscopie Digestive | 2018-06-24 |
| Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer (NCT03307564) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-06-06 |
| M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas (NCT03451773) | National Cancer Institute (NCI) | 2018-05-17 |
| Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms (NCT03468244) | Changhai Hospital | 2018-05-01 |
| Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology (NCT03703089) | Benaroya Research Institute | 2018-05-01 |
| Locally Advanced or Metastatic Pancreatic Adenocarcinoma (NCT03559348) | National Health Research Institutes, Taiwan | 2018-04-03 |
| A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer (NCT03528785) | Centro Ricerche Cliniche di Verona | 2018-03-02 |
| Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer (NCT03225989) | Lokon Pharma AB | 2018-03-01 |
| The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer (NCT03401827) | Seoul National University Hospital | 2018-03-01 |
| Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms (NCT03435770) | Singapore General Hospital | 2018-03-01 |
| EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging (NCT06341725) | Paolo Giorgio Arcidiacono, MD | 2018-02-15 |
| Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery (NCT03384238) | George Poultsides | 2018-02-07 |
| Utility of EUS-guided Microbiopsies in Pancreatic Cystic Lesions (NCT03578445) | Herlev Hospital | 2018-02-01 |
| Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (NCT03404960) | University of Pennsylvania | 2018-01-31 |
| Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) (NCT03415854) | HonorHealth Research Institute | 2018-01-31 |
| Laser Tissue Welding - Distal Pancreatectomy Sealing Study (NCT03147768) | Laser Tissue Welding, Inc. | 2018-01-01 |
| VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer (NCT03373188) | Emory University | 2017-12-15 |
| Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma (NCT03318497) | University of Texas Southwestern Medical Center | 2017-12-11 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| PEN-866 in Patients With Advanced Solid Malignancies (NCT03221400) | Tarveda Therapeutics | 2017-08-29 |
| Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma (NCT03080974) | University of Louisville | 2017-08-14 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (NCT03193190) | Hoffmann-La Roche | 2017-07-05 |
| Repeated EUS-guided Fine Needle Biopsy of Pancreatic Masses After Non-diagnostic or Inconclusive Results (NCT05226572) | University of Bologna | 2017-07-01 |
| Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic Adenocarcinoma. (NCT03202199) | Assistance Publique - Hôpitaux de Paris | 2017-06-19 |
| Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors (NCT03507998) | Curegenix Inc. | 2017-06-17 |
| Pre-operative Treatment for Patients With Untreated Pancreatic Cancer (NCT03138720) | HonorHealth Research Institute | 2017-05-23 |
| Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis (NCT03152487) | AdventHealth | 2017-04-24 |
| Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma (NCT03159819) | Changhai Hospital | 2017-04-01 |
| Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer (NCT02806687) | University Hospital, Toulouse | 2017-01-30 |